オプションチェーンは、WonderFi Techsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、WonderFi Techsの市場センチメントを評価します。.

WonderFi Techs (OTC:WONDF) 株価情報, オプションチェーン

WonderFi Technologies Inc is a technology company with the mission of creating digital access through its platforms. It operates in three segments: Trading, Payments, and Corporate. The Trading segment, comprising Bitbuy, Coinsquare, and CoinSmart crypto exchange platforms, generates the majority of the company's revenue.

WONDERFI TECHNOLOGIES INC by Wonderfi Technologies Inc.

WonderFi Technologies Inc

Crescent Capital BDC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCAP#NASDAQ">CCAP</a>) reported quarterly earnings of $0.45 per share which missed the analyst consensus estimate of $0.52 by 13.46 percent. This is a 28.57 percent decrease over earnings of $0.63 per share from the same period last year. The company reported quarterly sales of $42.13 million which missed the analyst consensus estimate of $45.08 million by 6.55 percent. This is a 16.35 percent decrease over sales of $50.36 million the same period last year.

Earnings

Earnings Misses

News

CCAP

Crescent Capital BDC Q1 Net investment income per share $0.45 Misses $0.52 Estimate, Total investment income $42.13M Miss $45.08M Estimate

Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 37.5 percent increase over losses of $(0.16) per share from the same period last year. The company reported $27.00 thousand in sales this quarter.

Earnings Beats

TLPH

Talphera Q1 EPS $(0.10) Beats $(0.14) Estimate, Sales $27.00K

The Beachbody Company, Inc. Class A Common Stock

BODI

The Beachbody Company, Inc. Class A Common Stock Q1 EPS $(0.84) Beats $(1.44) Estimate, Sales $72.40M Beat $64.18M Estimate

Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.24) by 25 percent. This is a 66.04 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $13.14 million which beat the analyst consensus estimate of $12.05 million by 9.00 percent. This is a 0.84 percent increase over sales of $13.03 million the same period last year.

DERM

Journey Medical Q1 EPS $(0.18) Beats $(0.24) Estimate, Sales $13.14M Beat $12.05M Estimate

SHIM

Shimmick Q1 Adj. EPS $(0.22) Beats $(0.25) Estimate, Sales $122.00M Beat $94.35M Estimate

Aterian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.69) by 24.64 percent. This is a 31.58 percent increase over losses of $(0.76) per share from the same period last year. The company reported quarterly sales of $15.36 million which beat the analyst consensus estimate of $14.95 million by 2.74 percent. This is a 24.01 percent decrease over sales of $20.21 million the same period last year.

ATER

Aterian Q1 EPS $(0.52) Beats $(0.69) Estimate, Sales $15.36M Beat $14.95M Estimate

Hawkins (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWKN#NASDAQ">HWKN</a>) reported quarterly earnings of $0.78 per share which beat the analyst consensus estimate of $0.73 by 6.85 percent. This is a 18.18 percent increase over earnings of $0.66 per share from the same period last year. The company reported quarterly sales of $245.32 million which beat the analyst consensus estimate of $230.69 million by 6.34 percent. This is a 10.00 percent increase over sales of $223.02 million the same period last year.

HWKN

Hawkins Q4 EPS $0.78 Beats $0.73 Estimate, Sales $245.32M Beat $230.69M Estimate

Azitra plans to dose first patient in a Phase 1/2 trial in the first half of 2025 for its precision dermatology candidate ATR04-484, designed for the treatment of EGFR inhibitor-associated rash

Biotech

Events

General

AZTR

Azitra To Present Phase 1/2 Study Of ATR04-484 For EGFR Inhibitor-Associated Rash

Guidance

SPIR

Spire Global Sees Q2 Adj EPS $(0.49)-$(0.42) vs $(0.47) Est; Sees Sales $18.000M-$20.000M vs $22.97M Est

SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.52) by 15.38 percent. This is a 90.74 percent increase over losses of $(4.75) per share from the same period last year. The company reported quarterly sales of $293.00 thousand which beat the analyst consensus estimate of $150.00 thousand by 95.33 percent.

SeaStar Medical Holding Q1 EPS $(0.44) Beats $(0.52) Estimate, Sales $293.00K Beat $150.00K Estimate

Fossil Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOSL#NASDAQ">FOSL</a>) reported quarterly losses of $(0.10) per share. This is a 66.67 percent increase over losses of $(0.30) per share from the same period last year. The company reported $233.30 million in sales this quarter. This is a 8.47 percent decrease over sales of $254.90 million the same period last year.

FOSL

Fossil Group Q1 Adj. EPS $(0.10) Up From $(0.30) YoY, Sales $233.30M Down From $254.90M YoY

Under the STEP 2.0 contract, the Company is eligible for future task orders to design, build, integrate, and operate small satellite buses for next-generation space experiments

Contracts

Spire Global Wins 10-Year U.S. Space Force Contract With $237M Ceiling

Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) reported quarterly losses of $(0.77) per share which missed the analyst consensus estimate of $(0.67) by 14.93 percent. This is a 45.28 percent decrease over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $23.90 million which beat the analyst consensus estimate of $22.68 million by 5.38 percent. This is a 6.96 percent decrease over sales of $25.69 million the same period last year.

Spire Global Q1 Adj. EPS $(0.77) Misses $(0.67) Estimate, Sales $23.90M Beat $22.68M Estimate

MRAI

Marpai Q1 EPS $(0.21) Up From $(0.46) YoY, Sales $5.42M Down From $7.38M YoY

Aytu BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYTU#NASDAQ">AYTU</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $(0.17) by 223.53 percent. This is a 140.38 percent increase over losses of $(0.52) per share from the same period last year. The company reported quarterly sales of $18.45 million which beat the analyst consensus estimate of $13.74 million by 34.30 percent. This is a 31.57 percent increase over sales of $14.03 million the same period last year.

AYTU

Aytu BioPharma Q3 EPS $0.21 Beats $(0.17) Estimate, Sales $18.45M Beat $13.74M Estimate

Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.52) by 11.54 percent. This is a 39.58 percent increase over losses of $(0.96) per share from the same period last year. The company reported quarterly sales of $6.81 million which missed the analyst consensus estimate of $7.28 million by 6.45 percent. This is a 0.86 percent increase over sales of $6.75 million the same period last year.

SSKN

Strata Skin Sciences Q1 EPS $(0.58) Misses $(0.52) Estimate, Sales $6.81M Miss $7.28M Estimate

Buybacks

Penske Automotive Group Increases Securities Repurchase Authorization By Additional $250M

Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a 35.29 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $2.33 million which beat the analyst consensus estimate of $170.00 thousand by 1.27K percent. This is a 913.04 percent increase over sales of $230.00 thousand the same period last year.

CLSD

Clearside Biomedical Q1 EPS $(0.11), Inline, Sales $2.33M Beat $170.00K Estimate

Star Bulk Carriers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBLK#NASDAQ">SBLK</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.28) by 75 percent. This is a 108.05 percent decrease over earnings of $0.87 per share from the same period last year. The company reported quarterly sales of $230.65 million which beat the analyst consensus estimate of $173.06 million by 33.28 percent. This is a 11.08 percent decrease over sales of $259.39 million the same period last year.

SBLK

Star Bulk Carriers Q1 Adj. EPS $(0.07) Beats $(0.28) Estimate, Sales $230.65M Beat $173.06M Estimate

Dividends

Penske Automotive Group Increases Quarterly Dividend From $1.22 To $1.26 Per Share

Lowering Of Rates Spurs Investment In Bitcoin And Other Digital Assets

Continued Crypto Adoption Pushes Shares Of This Crypto Trading Platform Higher

Press Releases

Alset AI Acquires Tokens of World's Largest Decentralized Artificial Intelligence Computing Network

Riot Platforms Announces Changes to Its Board of Directors and Provides Update on Formal Evaluation of AI/HPC Uses

BTCS Unveils Strategic Partnership with Figment and WonderFi Leading its Staker Protection Plan

BTCS Highlights Ethereum's Successful Pectra Upgrade

$BTC

ALSCF

BTCS

LINE

PCOR

RIOT

TSX:WNDR

TSXV:GPUS

WONDF

WonderFi Techs

Screenshot 2025-02-19 at 6.51.20 PM

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Comments

WonderFi Techs

WonderFi Techs (WONDF) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル